Overview

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Vanda Pharmaceuticals